A52.17
General paresis
Clinical Classification Guidelines
Inclusion Terms
- Dementia paralytica
Medical Intelligence & Overview
General paresis, also known as dementia paralytica, is a chronic neurological disorder resulting from the late-stage manifestation of untreated syphilis. It affects the brain and nervous system, leading to progressive mental and physical deterioration. Once a common complication of syphilis, advances in antibiotic treatment have significantly reduced its occurrence today. Nonetheless, understanding this condition is important for awareness and early intervention.
Causes & Symptoms
Clinical Causes: Untreated syphilis infection, particularly if left untreated for years Progression of the Treponema pallidum bacteria infiltrating the central nervous system Recurrent or inadequately treated syphilis cases that advance to the neurological stage
Key Symptoms: Memory loss and cognitive decline Altered mental state, confusion, or hallucinations Personality changes, including irritability and depression Muscle weakness or paralysis Difficulty coordinating movements (ataxia) Speech difficulties or slurred speech Sensory deficits or abnormal reflexes Seizures in some cases Progressive decline leading to coma in advanced stages
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of clinical evaluation, laboratory testing, and neurological assessment. Key diagnostic components include: - Blood tests for syphilis antibodies (e.g., RPR, VDRL) - Cerebrospinal fluid (CSF) analysis for detecting Treponema pallidum or antibodies - Neuroimaging studies, such as MRI or CT scans, to identify brain changes - Neurological examinations to assess cognitive and motor functions A thorough medical history, especially regarding previous syphilis infections, is essential for accurate diagnosis.
Treatment Protocols: The primary treatment for general paresis involves antibiotic therapy, typically penicillin, to eradicate Treponema pallidum bacteria. The specific regimen depends on the stage and severity of the disease. Treatment options include: - Intravenous penicillin therapy over a period of 10-14 days - Monitoring of cerebrospinal fluid for response to treatment - Supportive therapies aimed at managing neurological symptoms and improving quality of life - Regular follow-up to assess response and detect any recurrence Prompt diagnosis and treatment can halt disease progression, although some neurological damage may be irreversible.
Clinical Advice & FAQs
Billing Guidance
Is A52.17 a billable ICD-10 code?
Yes, A52.17 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report A52.17?
Clinical documentation must specify the nature of General paresis and any associated comorbidities for accurate reporting.
Cite this Clinical Reference